QUEST DIAGNOSTICS INC — Form 8-K
Filed October 22, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Quest Diagnostics reported Q3 2026 revenues of $3.10B (+10.0% YoY) and adjusted diluted EPS of $3.00 (+15.4% YoY), driven by strong organic requisition volume growth of 14.4%. The company raised full-year 2026 guidance: revenues to $12.065–$12.105B (prior $11.95–$12.05B) and adjusted diluted EPS to $11.25–$11.35 (prior $11.05–$11.25). Operating income margin expanded 40 bps on an adjusted basis. Notable developments include a definitive agreement to acquire select outreach lab assets in the Northeast, expansion of its Alzheimer's detection test panel, and a partnership enabling iPhone/iPad users to purchase Quest lab test panels via Apple Health.
Why this rating
Meaningful revenue and guidance lift (~$100M incremental revenue and ~$0.20 EPS upside relative to prior range) represent ~1% of $20B market cap. Strong organic growth and margin expansion are operationally solid but incremental, not transformational.
See more from October 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.